-+ 0.00%
-+ 0.00%
-+ 0.00%

Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC

PUBT·04/17/2026 10:00:38
Listen to the news
Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC
  • Kura Oncology reported preliminary data from ongoing FIT-001 trial of darlifarnib with cabozantinib in clear cell renal cell carcinoma patients previously treated with cabozantinib.
  • Results were presented at 2026 International Kidney Cancer Symposium (IKCS): Europe in Paris.
  • Subset analysis showed meaningful tumor responses in heavily pretreated patients, indicating potential to restore sensitivity to VEGF-targeted therapy.
  • Safety profile was described as manageable across tested dose levels, including regimens using full-dose cabozantinib.
  • Program advanced into Phase 1b dose expansion to select an optimal biologically active dose for further evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604170600PRIMZONEFULLFEED9691756) on April 17, 2026, and is solely responsible for the information contained therein.